GB9610967D0 - Specific binding members,materials and methods - Google Patents

Specific binding members,materials and methods

Info

Publication number
GB9610967D0
GB9610967D0 GB9610967A GB9610967A GB9610967D0 GB 9610967 D0 GB9610967 D0 GB 9610967D0 GB 9610967 A GB9610967 A GB 9610967A GB 9610967 A GB9610967 A GB 9610967A GB 9610967 D0 GB9610967 D0 GB 9610967D0
Authority
GB
United Kingdom
Prior art keywords
methods
materials
specific binding
binding members
specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GB9610967A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
Cambridge Antibody Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Antibody Technology Ltd filed Critical Cambridge Antibody Technology Ltd
Priority to GB9610967A priority Critical patent/GB9610967D0/en
Publication of GB9610967D0 publication Critical patent/GB9610967D0/en
Priority to TR1998/02416T priority patent/TR199802416T2/xx
Priority to UA98126836A priority patent/UA74129C2/uk
Priority to PL97330075A priority patent/PL188557B1/pl
Priority to SI9730765T priority patent/SI0906426T1/sl
Priority to EA199801043A priority patent/EA004329B1/ru
Priority to EP19970923243 priority patent/EP0906426B1/en
Priority to CA 2256308 priority patent/CA2256308C/en
Priority to US09/194,356 priority patent/US7273924B1/en
Priority to KR1020067006008A priority patent/KR100741452B1/ko
Priority to PT97923243T priority patent/PT906426E/pt
Priority to IL12721697A priority patent/IL127216A0/xx
Priority to CNB971949026A priority patent/CN100447159C/zh
Priority to AU29101/97A priority patent/AU729081B2/en
Priority to DK97923243T priority patent/DK0906426T3/da
Priority to ES97923243T priority patent/ES2286831T3/es
Priority to HU0200546A priority patent/HUP0200546A2/hu
Priority to JP54182897A priority patent/JP4750912B2/ja
Priority to NZ33308397A priority patent/NZ333083A/xx
Priority to BRPI9709350-5A priority patent/BR9709350B1/pt
Priority to DE1997637683 priority patent/DE69737683T2/de
Priority to PCT/GB1997/001412 priority patent/WO1997045544A1/en
Priority to AT97923243T priority patent/ATE361364T1/de
Priority to SK1612-98A priority patent/SK285916B6/sk
Priority to CZ19983815A priority patent/CZ295531B6/cs
Priority to KR10-2005-7000518A priority patent/KR20050010081A/ko
Priority to HK99105868.0A priority patent/HK1020990B/xx
Priority to IS4883A priority patent/IS2508B/is
Priority to NO19985459A priority patent/NO324904B1/no
Priority to IL127216A priority patent/IL127216A/en
Priority to BG102950A priority patent/BG65138B1/bg
Priority to US11/842,774 priority patent/US8703143B2/en
Priority to JP2008204682A priority patent/JP2009050261A/ja
Priority to US14/046,224 priority patent/US9096670B2/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
GB9610967A 1996-05-24 1996-05-24 Specific binding members,materials and methods Pending GB9610967D0 (en)

Priority Applications (34)

Application Number Priority Date Filing Date Title
GB9610967A GB9610967D0 (en) 1996-05-24 1996-05-24 Specific binding members,materials and methods
HK99105868.0A HK1020990B (en) 1996-05-24 1997-05-23 Antibodies to the ed-b domain of fibronectin, their construction and uses
HU0200546A HUP0200546A2 (en) 1996-05-24 1997-05-23 Antibodies to the ed-b domain of fibronectin, their construction and uses
JP54182897A JP4750912B2 (ja) 1996-05-24 1997-05-23 フィブロネクチンのｅｄ―ｂドメインに対する抗体、それらの構造及び用途
PL97330075A PL188557B1 (pl) 1996-05-24 1997-05-23 Sposób wytwarzania swoiście wiążącego się czynnika, swoiście wiążący się czynnik, kwas nukleinowy ifag
SI9730765T SI0906426T1 (sl) 1996-05-24 1997-05-23 Protitelesa proti ED-B domeni fibronektina, njihova konstrukcija in njihove uporabe
EA199801043A EA004329B1 (ru) 1996-05-24 1997-05-23 Антитела против домена ed-b фибронектина, их конструирование и использование
EP19970923243 EP0906426B1 (en) 1996-05-24 1997-05-23 Antibodies to the ed-b domain of fibronectin, their construction and uses
CA 2256308 CA2256308C (en) 1996-05-24 1997-05-23 Antibodies to the ed-b domain of fibronectin, their construction and uses
US09/194,356 US7273924B1 (en) 1996-05-24 1997-05-23 Antibodies to the ED-B domain of fibronectin, their construction and uses
KR1020067006008A KR100741452B1 (ko) 1996-05-24 1997-05-23 피브로넥틴 ｅｄ-ｂ 도메인에 대한 항체, 그 제조방법 및용도
PT97923243T PT906426E (pt) 1996-05-24 1997-05-23 Anticorpos para o domínio ed-b de fibronectina, sua construção e utilizações
BRPI9709350-5A BR9709350B1 (pt) 1996-05-24 1997-05-23 anticorpo recombinante ou fragmento de anticorpo recombinante, composiÇço farmacÊutica, Ácido nuclÈico, bacteriàfago, cÉlula hospedeira bacteriana ou de levedura, uso de anticorpo ou fragmento de anticorpo recombinante, processo para a produÇço do mesmo, e, kit diagnàstico.
CNB971949026A CN100447159C (zh) 1996-05-24 1997-05-23 结合纤连蛋白ed-b结构域的抗体及其构建和应用
AU29101/97A AU729081B2 (en) 1996-05-24 1997-05-23 Antibodies to the ED-B domain of fibronectin, their construction and uses
DK97923243T DK0906426T3 (da) 1996-05-24 1997-05-23 Antistoffer mod ED-B-domænet af fibronektin, deres konstruktion og anvendelser
ES97923243T ES2286831T3 (es) 1996-05-24 1997-05-23 Anticuerpos para el dominio ed-b de fibronectina, la construccion de estos y sus usos.
TR1998/02416T TR199802416T2 (xx) 1996-05-24 1997-05-23 Fibronektinin ED-B b�lgesi i�in antikorlar, yap�lar� ve kullan�mlar�.
NZ33308397A NZ333083A (en) 1996-05-24 1997-05-23 Antibodies to the ED-B domain of fibronectin (FN), their construction and uses
UA98126836A UA74129C2 (uk) 1996-05-24 1997-05-23 Виділене антитіло або фрагмент антитіла, що є специфічним до онкоембріонального домену ed-b фібронектину (fn) та таким, що безпосередньо з ним зв'язується
IL12721697A IL127216A0 (en) 1996-05-24 1997-05-23 Antibodies to the ed-b domain of fibronectin their construction and uses
DE1997637683 DE69737683T2 (de) 1996-05-24 1997-05-23 Antikörper gegen die ed-b domäne von fibronektin, ihre herstellung und verwendungen
PCT/GB1997/001412 WO1997045544A1 (en) 1996-05-24 1997-05-23 Antibodies to the ed-b domain of fibronectin, their construction and uses
AT97923243T ATE361364T1 (de) 1996-05-24 1997-05-23 Antikörper gegen die ed-b domäne von fibronektin, ihre herstellung und verwendungen
SK1612-98A SK285916B6 (sk) 1996-05-24 1997-05-23 Protilátky proti ED-B doméne fibronektínu, ich konštrukcia a použitie
CZ19983815A CZ295531B6 (cs) 1996-05-24 1997-05-23 Izolovaná protilátka, způsob její výroby a použití
KR10-2005-7000518A KR20050010081A (ko) 1996-05-24 1997-05-23 피브로넥틴 ｅｄ-ｂ 도메인에 대한 항체, 그 제조방법 및용도
IS4883A IS2508B (is) 1996-05-24 1998-10-29 Mótefni gegn ED-B hneppinu í fíbrónektíni, smíði þeirra og notkanir
NO19985459A NO324904B1 (no) 1996-05-24 1998-11-23 Antistoff eller antistoffragment rettet mot ED-B domenenet til fibronektin, farmasoytisk sammensetning, nukleinsyre, fag, vertcelle, fremgangsmate for fremstilling, ulike anvendelser samt diagnostisk kit
IL127216A IL127216A (en) 1996-05-24 1998-11-23 Antibody-specific antibody or fragment - Fibronectin B – ED embryos, process for their preparation and use
BG102950A BG65138B1 (bg) 1996-05-24 1998-11-24 Антитела за ed-b домен на фибронектин, техният строеж и използвания
US11/842,774 US8703143B2 (en) 1996-05-24 2007-08-21 Antibodies of the ED-B domain of fibronectin, their construction and uses
JP2008204682A JP2009050261A (ja) 1996-05-24 2008-08-07 フィブロネクチンのｅｄ―ｂドメインに対する抗体、それらの構造及び用途
US14/046,224 US9096670B2 (en) 1996-05-24 2013-10-04 Antibodies of the ED-B domain of fibronectin, their construction and uses

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9610967A GB9610967D0 (en) 1996-05-24 1996-05-24 Specific binding members,materials and methods

Publications (1)

Publication Number Publication Date
GB9610967D0 true GB9610967D0 (en) 1996-07-31

Family

ID=10794298

Family Applications (1)

Application Number Title Priority Date Filing Date
GB9610967A Pending GB9610967D0 (en) 1996-05-24 1996-05-24 Specific binding members,materials and methods

Country Status (28)

Country Link
US (3) US7273924B1 (enExample)
EP (1) EP0906426B1 (enExample)
JP (2) JP4750912B2 (enExample)
KR (2) KR100741452B1 (enExample)
CN (1) CN100447159C (enExample)
AT (1) ATE361364T1 (enExample)
AU (1) AU729081B2 (enExample)
BG (1) BG65138B1 (enExample)
BR (1) BR9709350B1 (enExample)
CA (1) CA2256308C (enExample)
CZ (1) CZ295531B6 (enExample)
DE (1) DE69737683T2 (enExample)
DK (1) DK0906426T3 (enExample)
EA (1) EA004329B1 (enExample)
ES (1) ES2286831T3 (enExample)
GB (1) GB9610967D0 (enExample)
HU (1) HUP0200546A2 (enExample)
IL (2) IL127216A0 (enExample)
IS (1) IS2508B (enExample)
NO (1) NO324904B1 (enExample)
NZ (1) NZ333083A (enExample)
PL (1) PL188557B1 (enExample)
PT (1) PT906426E (enExample)
SI (1) SI0906426T1 (enExample)
SK (1) SK285916B6 (enExample)
TR (1) TR199802416T2 (enExample)
UA (1) UA74129C2 (enExample)
WO (1) WO1997045544A1 (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
GB9610967D0 (en) 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
US6685943B1 (en) 1997-01-21 2004-02-03 The Texas A&M University System Fibronectin binding protein compositions and methods of use
US7244826B1 (en) 1998-04-24 2007-07-17 The Regents Of The University Of California Internalizing ERB2 antibodies
US20030176663A1 (en) * 1998-05-11 2003-09-18 Eidgenossische Technische Hochscule Specific binding molecules for scintigraphy
TWI259837B (en) * 1998-05-11 2006-08-11 Eidgenossische Tech Hochscule Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
US20030045681A1 (en) * 1998-05-11 2003-03-06 Anthony J. Zelano Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
EP1259548A1 (en) * 2000-02-24 2002-11-27 Eidgenössische Technische Hochschule Zürich Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis
CA2399866C (en) * 2000-02-24 2011-05-10 Philogen S.R.L. Compositions and methods for treatment of angiogenesis in pathological lesions
EP1282642B1 (en) 2000-05-09 2006-09-06 Greenville Hospital System Therapeutic pore-forming peptides
AU2001281824A1 (en) * 2000-06-15 2001-12-24 Patrizia Castellani Methods for quantitative determination of b-fibronectin in biological fluids and tissues
AU1218202A (en) * 2000-09-07 2002-03-22 Schering Ag Receptor in the ED<sub>b</sub> fibronectin domain
IT1317108B1 (it) * 2000-12-06 2003-05-26 Philogen Srl Processo per la selezione di frammenti anticorporali anti-angiogenesi,frammenti anticorpali anti-angiogenesi cosi' ottenuti e loro uso.
US7456146B2 (en) * 2001-05-09 2008-11-25 Ghc Research Development Corporation Lytic peptide prodrugs
MXPA04006517A (es) 2002-01-03 2005-03-31 Schering Ag Conjugados que comprenden un anticuerpo especifico para el dominio ed-b de fibronectina y sus usos para la deteccion y tratamiento de tumores.
SI1483297T1 (sl) * 2002-03-11 2010-04-30 Philogen Spa Protitelesa, izvedena iz anti ED-B L19, in ki ciljajo vaskulaturo tumorja
KR20110025885A (ko) 2002-07-15 2011-03-11 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 포스파티딜에탄올아민에 결합하는 펩타이드, 및 바이러스 감염을 치료하는데 있어서 이의 용도
JP4914209B2 (ja) 2003-03-14 2012-04-11 ワイス ヒトｉｌ−２１受容体に対する抗体および該抗体の使用
DE10324447A1 (de) 2003-05-28 2004-12-30 Scil Proteins Gmbh Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin
US8420087B2 (en) 2004-01-05 2013-04-16 Antisoma Research Limited Interleukin-12 targeted to oncofoetal fibronectin
AU2005280528B2 (en) 2004-07-30 2010-12-23 Adeza Biomedical Corporation Oncofetal fibronectin as a marker for disease and other conditions and methods for detection of oncofetal fibronectin
US7785591B2 (en) 2004-10-14 2010-08-31 Morphosys Ag Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
EP1803814A1 (en) 2005-12-27 2007-07-04 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Method of improving the antibody selection capacity in phage-display library
EP1925664A1 (en) 2006-11-15 2008-05-28 Scil proteins GmbH Artificial binding proteins based on a modified alpha helical region of ubiquitin
US8253725B2 (en) * 2007-12-28 2012-08-28 St. Jude Medical, Atrial Fibrillation Division, Inc. Method and system for generating surface models of geometric structures
EP2085095B1 (en) * 2008-01-17 2012-03-07 Philogen S.p.A. Combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpart
EP2100621A1 (en) 2008-03-10 2009-09-16 mivenion GmbH Polyether polyol dendron conjugates with effector molecules for biological targeting
EP2116555A1 (en) 2008-05-08 2009-11-11 Bayer Schering Pharma Aktiengesellschaft Use of a radioactively labelled molecule specifically binding to ED-B fibronectin in a method of treatment of Hodgkin lymphoma
IT1392027B1 (it) * 2008-12-12 2012-02-09 Castellani Anticorpo monoclonale e suo uso per la identificazione della isoforma oncofetale della fibronettina (b-fn) a scopo diagnostico o terapeutico.
BR112012014194A2 (pt) 2009-12-14 2017-01-10 Scil Proteins Gmbh um método para identificar proteínas ubiquitinas modificadas hetero-multiméricas com capacidade de ligação a ligandos
WO2011110490A1 (en) 2010-03-09 2011-09-15 Bayer Pharma Aktiengesellschaft Process for the production of radioactively labelled scfv antibody fragments, kits and compositions
WO2012171541A1 (en) 2011-06-15 2012-12-20 Scil Proteins Gmbh Human fusion proteins comprising interferons and hetero-dimeric modified ubiquitin proteins
EP2721152B1 (en) 2011-06-15 2019-03-27 Navigo Proteins GmbH Dimeric binding proteins based on modified ubiquitins
US20150183846A1 (en) 2012-06-13 2015-07-02 Scil Proteins Gmbh Human fusion proteins comprising single chain tnfalpha and targeting domains
WO2014094799A1 (en) 2012-12-19 2014-06-26 Scil-Proteins-Gmbh Ubiquitin moieties as a means for prolonging serum half-life
WO2014194784A1 (zh) * 2013-06-06 2014-12-11 合肥立方制药股份有限公司 人源抗纤连蛋白ed-b结构域的抗体及其用途
JP6738340B2 (ja) 2015-02-06 2020-08-12 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ 新規なｅｇｆｒ結合タンパク質
ES2916101T3 (es) 2015-07-16 2022-06-28 Navigo Proteins Gmbh Nuevas proteínas de unión a inmunoglobulina y su uso en la purificación por afinidad
JP2018520675A (ja) 2015-07-20 2018-08-02 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ ジユビキチン変異タンパク質をベースとした新規結合タンパク質及びその生成方法
CN108291915B (zh) * 2015-11-16 2021-01-05 合肥立方制药股份有限公司 Ed-b蛋白在诊断组织增生中的应用
JP2019526526A (ja) 2016-05-04 2019-09-19 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ ペプチドリンカーを含む化学的部分の部位特異的カップリングのための標的化合物
DK3497117T5 (da) 2016-08-11 2024-09-02 Navigo Proteins Gmbh Nye alkalisk stabile immunglobulin-bindende proteiner
JP7039577B2 (ja) 2016-10-17 2022-03-22 ファイザー・インク 抗ｅｄｂ抗体および抗体－薬物コンジュゲート
CA3065153C (en) 2017-06-07 2023-09-05 Philogen S.P.A. Vascular endothelial growth factor/anti-fibronectin antibody fusion proteins
US11192943B2 (en) 2017-09-30 2021-12-07 Hefei Lifeon Pharmaceutical Co., Ltd. Protein binding to fibronectin B domain
EP3706804B1 (en) 2017-11-07 2022-02-23 Navigo Proteins GmbH Fusion proteins with specificity for ed-b and long serum half-life for diagnosis or treatment of cancer
WO2020070150A1 (en) 2018-10-02 2020-04-09 Philogen S.P.A Il2 immunoconjugates
EP3660039A1 (en) 2018-11-30 2020-06-03 Philogen S.p.A. Il2 immunoconjugates
PH12022550348A1 (en) 2019-08-15 2022-12-12 Janssen Biotech Inc Materials and methods for improved single chain variable fragments
US20210188990A1 (en) 2019-12-11 2021-06-24 Cilag Gmbh International Multispecific binding molecules comprising ltbr and edb binding domains and uses thereof
CN111171149B (zh) * 2020-02-23 2021-09-07 北京康普美特创新医药科技有限责任公司 一种抗补体c5分子的人源化单链抗体及其应用
CN111234016B (zh) * 2020-02-23 2021-09-07 北京康普美特创新医药科技有限责任公司 一种抗补体c5分子的全人源单克隆抗体及应用
KR102614063B1 (ko) 2020-12-24 2023-12-19 대화제약 주식회사 엑스트라도메인 b 피브로넥틴에 특이적으로 결합하는 신규한 항체
CA3242326A1 (en) 2022-01-04 2023-07-13 Cipo Combination of an immunocytokine comprising il-12 and a kinase inhibitor
US20250262307A1 (en) 2022-08-01 2025-08-21 Philochem Ag Conjugates of psma-binding moieties with cytotoxic agents
WO2024052333A1 (en) 2022-09-06 2024-03-14 Philochem Ag Multivalent fibroblast activation protein ligands for targeted delivery applications
WO2025061801A1 (en) 2023-09-19 2025-03-27 Philochem Ag Therapeutic combination of an anti-edb fibronectin domain antibody il2 or il12 fusion protein and a lutetium-177 radioconjugate
WO2025221736A2 (en) 2024-04-15 2025-10-23 Janssen Biotech, Inc. Ltbr binding molecules and uses thereof

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
EP0211047B1 (en) 1985-01-28 1994-02-02 Xoma Corporation Arab promoters and method of producing polypeptides, includinn cecropins, by microbiological techniques
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5243029A (en) 1986-04-09 1993-09-07 Fred Hutchinson Cancer Research Center Oncofetal structure of fibronectin
US4894326A (en) 1986-04-09 1990-01-16 Fred Hutchinson Cancer Research Center Monoclonal antibody defining oncofetal structure of fibronectin
CA1341235C (en) 1987-07-24 2001-05-22 Randy R. Robinson Modular assembly of antibody genes, antibodies prepared thereby and use
JPH02598A (ja) * 1987-10-09 1990-01-05 De La Rue Co Plc:The 集積回路カード
ATE140731T1 (de) 1988-01-11 1996-08-15 Xoma Corp Plasmidvektor mit pectatlyase-signalsequenz
IT1217724B (it) 1988-05-26 1990-03-30 Ist Naz Ric Sul Cancro Anticorpo monoclonale specifico per una sequenza di fibronettina espressa in cellule trasformate ibridoma secernente tale anticorpo e impiego dell'anticorpo monoclonale per la diagnosi di tumori
US5177015A (en) 1988-08-12 1993-01-05 Fred Hutchinson Cancer Research Centre Onco-developmentally regulated α-N-acetylgalactosaminyltransferase
US5843156A (en) 1988-08-24 1998-12-01 Endoluminal Therapeutics, Inc. Local polymeric gel cellular therapy
JPH0276598A (ja) 1988-09-14 1990-03-15 Fujita Gakuen 抗ｅｄ−ｂ抗体
JPH04169195A (ja) 1990-10-31 1992-06-17 Fujita Gakuen 抗ｅｄ―ｂモノクローナル抗体
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
US5629291A (en) 1992-01-31 1997-05-13 La Jolla Cancer Research Foundation Methods of modulating fibronectin extracellular matrix assembly
US6004555A (en) 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
US6093399A (en) 1992-03-05 2000-07-25 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US6036955A (en) 1992-03-05 2000-03-14 The Scripps Research Institute Kits and methods for the specific coagulation of vasculature
US5877289A (en) 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5976535A (en) 1992-06-09 1999-11-02 Neorx Corporation Pretargeting protocols for the enhanced localization of cytotoxins to target sites and cytotoxic combinations useful therefore
CA2123699C (en) 1992-09-25 1999-12-07 Takashi Komai An adsorbent for cellular fibronectin, a method for fractional purification of fibronectin and a method of hemocatharisis
US5491130A (en) 1992-11-10 1996-02-13 The United States Of America As Represented By The Department Of Health And Human Services Peptide inhibitors of fibronectin and related collagen-binding proteins
EP0672142B1 (en) 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US6015897A (en) 1993-12-07 2000-01-18 Neorx Corporation Biotinamido-n-methylglycyl-seryl-o-succinamido-benzyl dota
US5523229A (en) 1994-03-22 1996-06-04 Trustees Of The University Of Pennsylvania Antibodies specific for oncofetal fibronectin
DE4417865A1 (de) 1994-05-20 1995-11-23 Behringwerke Ag Kombination von Tumornekrose-induzierenden Substanzen mit Substanzen, die durch Nekrosen aktiviert werden, zur selektiven Tumortherapie
ITFI940095A1 (it) 1994-05-23 1995-11-23 Molteni & C Coniugati fotodinamici aventi proprieta' biocide
US5648485A (en) 1994-10-26 1997-07-15 University Of British Columbia β, β-dihydroxy meso-substituted chlorins, isobacteriochlorins, and bacteriochlorins
WO1996023816A1 (en) 1995-02-01 1996-08-08 British Technology Group Limited Radiolabelled proteins
WO1997002479A2 (en) 1995-06-30 1997-01-23 Yale University Human monoclonal anti-tumor antibodies
US5808146A (en) 1995-11-09 1998-09-15 Emory University Amino acid analogs for tumor imaging
GB9610967D0 (en) 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
US5913884A (en) 1996-09-19 1999-06-22 The General Hospital Corporation Inhibition of fibrosis by photodynamic therapy
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
US6267722B1 (en) 1998-02-03 2001-07-31 Adeza Biomedical Corporation Point of care diagnostic systems
US6394952B1 (en) 1998-02-03 2002-05-28 Adeza Biomedical Corporation Point of care diagnostic systems
TWI259837B (en) 1998-05-11 2006-08-11 Eidgenossische Tech Hochscule Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
CA2399866C (en) 2000-02-24 2011-05-10 Philogen S.R.L. Compositions and methods for treatment of angiogenesis in pathological lesions
EP1259548A1 (en) 2000-02-24 2002-11-27 Eidgenössische Technische Hochschule Zürich Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis
MXPA04006517A (es) 2002-01-03 2005-03-31 Schering Ag Conjugados que comprenden un anticuerpo especifico para el dominio ed-b de fibronectina y sus usos para la deteccion y tratamiento de tumores.
JP4169195B2 (ja) * 2003-06-24 2008-10-22 株式会社河合楽器製作所 電子楽音発生装置の記録制御装置

Also Published As

Publication number Publication date
IL127216A (en) 2008-11-26
HK1020990A1 (zh) 2000-05-26
BR9709350A (pt) 2000-01-04
SK285916B6 (sk) 2007-11-02
IS2508B (is) 2009-04-15
BR9709350B1 (pt) 2010-12-14
CN1219968A (zh) 1999-06-16
CZ295531B6 (cs) 2005-08-17
NO985459D0 (no) 1998-11-23
BG65138B1 (bg) 2007-03-30
KR100741452B1 (ko) 2007-07-20
SK161298A3 (en) 1999-07-12
AU729081B2 (en) 2001-01-25
CN100447159C (zh) 2008-12-31
US8703143B2 (en) 2014-04-22
US20080274099A1 (en) 2008-11-06
CA2256308A1 (en) 1997-12-04
IS4883A (is) 1998-10-29
PL330075A1 (en) 1999-04-26
TR199802416T2 (xx) 1999-02-22
AU2910197A (en) 1998-01-05
JP2000511416A (ja) 2000-09-05
US9096670B2 (en) 2015-08-04
EA004329B1 (ru) 2004-04-29
PT906426E (pt) 2007-07-23
EA199801043A1 (ru) 1999-04-29
EP0906426A1 (en) 1999-04-07
DE69737683T2 (de) 2008-01-10
JP4750912B2 (ja) 2011-08-17
NO985459L (no) 1999-01-22
JP2009050261A (ja) 2009-03-12
IL127216A0 (en) 1999-09-22
DK0906426T3 (da) 2007-09-10
ES2286831T3 (es) 2007-12-01
US20140134182A1 (en) 2014-05-15
ATE361364T1 (de) 2007-05-15
US7273924B1 (en) 2007-09-25
KR20060035812A (ko) 2006-04-26
CA2256308C (en) 2012-03-13
DE69737683D1 (de) 2007-06-14
WO1997045544A1 (en) 1997-12-04
UA74129C2 (uk) 2005-11-15
SI0906426T1 (sl) 2007-10-31
BG102950A (en) 1999-08-31
HUP0200546A2 (en) 2002-07-29
PL188557B1 (pl) 2005-02-28
EP0906426B1 (en) 2007-05-02
NO324904B1 (no) 2007-12-27
CZ381598A3 (cs) 1999-03-17
NZ333083A (en) 2000-05-26
KR20050010081A (ko) 2005-01-26

Similar Documents

Publication Publication Date Title
GB9610967D0 (en) Specific binding members,materials and methods
AU8817391A (en) Method for the production of antibodies
AU1843395A (en) Antibody purification
IL135590A0 (en) A process for the reduction of oxiranyl epothilones to olefinic epothilones
MY125565A (en) Intermediates and process for preparing olanzapine
AU5686698A (en) Methods for the production of chicken monoclonal antibodies
AU1582197A (en) Combinatorial process for preparing substituted indane libraries
CR5406S (es) Encendedor util
GB2342652A (en) Polypeptides comprising a coiled-coil and an addition
DE69729211D1 (en) Tetrahydro-beta carbolinverbindungen
BG108682A (en) Method for the production of transparent flexible container, and container produced therewith
TR199700976A3 (tr) Liflerin ön muamelesi için terkip.
PL345195A1 (en) Morphine-6-glucuronide synthesis
WO1999028465A3 (en) Pias molecules that recognize and bind stat proteins and uses thereof
AU7214298A (en) Process for making a butylthio-isoquinoline and intermediates therefor
EP0971885A4 (en) METHOD FOR PRODUCING INDAN-LIKE CONNECTIONS
AU2024497A (en) Cycloalkyl derivatives and the solid-phase synthesis of such derivatives
ATE258559T1 (de) Ks-laminin und methoden zur verwendung
TW288020B (en) Monoclonal antibodies specific to methamphetamine, hybridoma producing the antibodies, kits containing the antibodies and uses thereof
WO1999040078A3 (en) Process for the preparation of sotolon
WO1999032507A3 (en) Intermediates and process for the synthesis of 17-unsubstituted 16.beta.-aryloxy 4-azasteroids
CR5405S (es) Encendedor util
HUP0003029A2 (hu) Ankrod specifikus monoklonális antitestek, antitestfragmentumok, keverékeik és alkalmazásuk
MX9703752A (es) Proceso y compuestos intermedios para la preparacion de compuestos pesticidas de fluoroolefinas.
DK15393D0 (da) Strengeholder til musikinstrumenter